Login to your account
Don’t have an account?
Create a Free Account
FREE ISSUE
November 2009
Volume 8Issue 10p785-820
Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of mTOR Inhibitors
Cover images, from left to right:Progression-free survival (PFS) in patients with
metastatic renal cell carcinoma treated with everolimus (n = 277; median PFS 4.90
mo) or placebo (n = 139; median PFS 1.87 mo). Motzer et al. Presentation at ASCO 2009
Genitourinary Cancer Symposium (Abstract 278).Lung computed tomography scan of a patient
with metastatic renal cell carcinoma before (middle) and 16 mo after treatment with
everolimus showing evidence of metastatic regression (right). Reproduced with kind
permission of Alain Ravaud....Show more
Cover images, from left to right:Progression-free survival (PFS) in patients with
metastatic renal cell carcinoma treated with everolimus (n = 277; median PFS 4.90
mo) or placebo (n = 139; median PFS 1.87 mo). Motzer et al. Presentation at ASCO 2009
Genitourinary Cancer Symposium (Abstract 278).Lung computed tomography scan of a patient
with metastatic renal cell carcinoma before (middle) and 16 mo after treatment with
everolimus showing evidence of metastatic regression (right). Reproduced with kind
permission of Alain Ravaud.
